Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The paediatric liver transplant experience in Johannesburg, South Africa: A broad overview and update.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2024

Same author

The effect of a home-based, gamified stability skills intervention on 4-5-year-old children's physical and cognitive outcomes: A pilot study.

Psychology of sport and exercise·2024

Same author

The influence of fear of falling on the control of upright stance across the lifespan.

Gait & posture·2024

Same author

Help-seeking intentions of UK construction workers: a cross-sectional study.

Occupational medicine (Oxford, England)·2024

Same author

Cognitive mechanisms and resilience in UK-based general practitioners: cross-sectional findings.

Occupational medicine (Oxford, England)·2023

Same author

Two Consecutive Invasive Surgeries Utilizing Zymogen Protein C (ZPC) That Enhanced Patient Safety and Reduced Costs.

Advances in experimental medicine and biology·2021

Search research articles

Related Experiment Video

Updated: Jul 23, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.

M J Olnes¹, T Nicol, M Duncan

¹Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD 21224, USA, USA.

Leukemia & Lymphoma

|August 3, 2002

Summary

Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive cancer. A recent case study shows that ABVD chemotherapy can be an effective treatment, leading to a complete response.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: Jul 23, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

Oncology
Pathology

Background:

Interdigitating dendritic cell sarcoma (IDCS) is an exceptionally rare and aggressive neoplasm, with fewer than 25 reported cases globally.
Diagnosis is challenging due to its rarity and subtle histopathologic features, often confused with reticular cell tumors.

Observation:

A 44-year-old female presented with abdominal pain and inguinal adenopathy, indicative of advanced IDCS.
Staging revealed extensive inguinal, abdominal, and liver involvement, including a mass encasing the small bowel.

Findings:

Morphologic, cytochemical, and immunohistochemical analyses confirmed the IDCS diagnosis.
Immunohistochemistry was positive for CLA, Kp-1, and S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.

Implications:

The patient achieved rapid clinical improvement and a complete response after six cycles of ABVD chemotherapy.
This case suggests ABVD chemotherapy may be a viable and effective treatment option for interdigitating dendritic cell sarcoma, addressing the lack of consensus on therapeutic regimens.